Ignite Creation Date:
2024-05-05 @ 4:52 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00333112
Status:
COMPLETED
Last Update Posted:
2014-09-18
First Post:
2006-06-01
Brief Title:
A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms OAB in Men
Sponsor:
Astellas Pharma Inc
Organization:
Astellas Pharma Inc
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Parallel Group Multicenter Safety and Efficacy Phase 4 Study of VESIcare Solifenacin Succinate or Placebo in Combination With Tamsulosin HCl for the Treatment of Residual OAB Symptoms of Urgency and Frequency in Men VICTOR VESIcare In Combination With Tamsulosin in OAB Residual Symptoms
Status:
COMPLETED
Status Verified Date:
2014-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
VICTOR
Brief Summary:
A study to evaluate solifenacin succinate in combination with tamsulosin for the treatment of residual OAB symptoms in men
Detailed Description:
A 2 arm study 1 Active 1 Placebo to evaluate solifenacin succinate in combination with tamsulosin for the treatment of residual OAB symptoms in men
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None